Imaging data from the phase 2 MINDFuL trial in Alzheimer’s Disease should be released in Q4 2025. Final data on the INKmune CARE-PC trial is expected in Q4 2025. Financial Results for the Third ...

Despite massive advancements in Cancer treatment in the last few decades, Cancer still remains one of the most fatal ...

Analysis of the first 9 patients treated showed evidence of NK cell proliferation in vivo and generation ... company focused on developing treatments that target the innate immune system to fight ...

Researchers at Baylor College of Medicine have discovered that certain p53 mutants hijack the DNA replication machinery ...

Researchers discovered that some p53 mutations, particularly R273H, overstimulate DNA replication and trigger immune ...

Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that it has received Orphan Drug Designation ...

Decades of tensions with Iran culminated in the short but sharp 12-Day War in June. The United States and Israel won the battle, but this is just one round in the war Tehran still intends to win.

The gene p53 acts as a tumor suppressor and is often called the guardian of the genome. This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading to ...

Decades of tensions with Iran culminated in the short but sharp 12-Day War in June. The United States and Israel won the ...

The articles in this focus issue discuss progress towards a more complete understanding of memory in the innate immune system, and efforts to exploit "trained immunity" for the development of new ...